{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T23:49:14Z","timestamp":1781912954419,"version":"3.54.5"},"publisher-location":"New York, NY","reference-count":29,"publisher":"Springer New York","isbn-type":[{"value":"9781493966530","type":"print"},{"value":"9781493966554","type":"electronic"}],"license":[{"start":{"date-parts":[[2016,11,22]],"date-time":"2016-11-22T00:00:00Z","timestamp":1479772800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/978-1-4939-6655-4_19","type":"book-chapter","created":{"date-parts":[[2016,11,22]],"date-time":"2016-11-22T01:25:45Z","timestamp":1479777945000},"page":"255-265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas"],"prefix":"10.1007","author":[{"given":"Lauren P.","family":"McLaughlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Gottschalk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cliona M.","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Bollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,22]]},"reference":[{"key":"19_CR1","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1172\/JCI61245","volume":"122","author":"R Kuppers","year":"2012","unstructured":"Kuppers R, Engert A, Hansmann ML (2012) Hodgkin lymphoma. J Clin Invest 122:3439\u20133447","journal-title":"J Clin Invest"},{"key":"19_CR2","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1136\/jcp.2007.051953","volume":"60","author":"KL Grogg","year":"2007","unstructured":"Grogg KL, Miller RF, Dogan A (2007) HIV infection and lymphoma. J Clin Pathol 60:1365\u20131372","journal-title":"J Clin Pathol"},{"key":"19_CR3","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1182\/blood-2010-06-292268","volume":"116","author":"CP Fox","year":"2010","unstructured":"Fox CP, Haigh TA, Taylor GS et al (2010) A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood 116:3695\u20133704","journal-title":"Blood"},{"key":"19_CR4","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1182\/blood.V89.6.1978","volume":"89","author":"AP Sing","year":"1997","unstructured":"Sing AP, Ambinder RF, Hong DJ et al (1997) Isolation of Epstein-Barr Virus (EBV)-Specific cytotoxic T Lymphocytes that lyse reed-sternberg cells: implications for immune-medicated therapy of EBV hodgkin\u2019s disease. Blood 89:1978\u20131986","journal-title":"Blood"},{"issue":"1","key":"19_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/mt.2013.242","volume":"22","author":"WK Chia","year":"2014","unstructured":"Chia WK, Teo M, Wang WW et al (2014) Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and\/or locally recurrent nasopharyngeal carcinoma. Mol Ther 22(1):132\u2013139","journal-title":"Mol Ther"},{"issue":"6533","key":"19_CR6","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/375685a0","volume":"375","author":"J Levitskaya","year":"1995","unstructured":"Levitskaya J, Coram M, Levitsky V et al (1995) Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375(6533):685\u2013688","journal-title":"Nature"},{"key":"19_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","volume":"345","author":"CM Rooney","year":"1995","unstructured":"Rooney CM, Smith CA, Ng C et al (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 345:9\u201313","journal-title":"Lancet"},{"key":"19_CR8","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJM199404283301703","volume":"330","author":"EB Papadopoulos","year":"1994","unstructured":"Papadopoulos EB, Ladanyi M, Emanuel D et al (1994) Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 330:1185\u20131191","journal-title":"N Engl J Med"},{"key":"19_CR9","first-page":"149","volume-title":"Important advances in oncology 1996","author":"RJ O\u2019Reilly","year":"1996","unstructured":"O\u2019Reilly RJ, Lacerda JF, Lucas KG et al (1996) Adoptive cell therapy with donor lymphocytes for EBV-associated lymphomas developing after allogeneic marrow transplants. In: DeVita VT, Hellman S, Rosenberg SA (eds) Important advances in oncology 1996. Lippincott-Raven, Philadelphia, pp 149\u2013166"},{"issue":"11","key":"19_CR10","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","volume":"119","author":"E Doubrovina","year":"2012","unstructured":"Doubrovina E, Oflaz-Sozmen B, Prockop SE et al (2012) Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 119(11):2644\u20132656","journal-title":"Blood"},{"key":"19_CR11","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nm0596-551","volume":"2","author":"HE Heslop","year":"1996","unstructured":"Heslop HE, Ng CYC, Li C et al (1996) Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2:551\u2013555","journal-title":"Nat Med"},{"issue":"5","key":"19_CR12","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","volume":"115","author":"HE Heslop","year":"2010","unstructured":"Heslop HE, Slobod KS, Pule MA et al (2010) Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115(5):925\u2013935","journal-title":"Blood"},{"issue":"4","key":"19_CR13","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","volume":"110","author":"T Haque","year":"2007","unstructured":"Haque T, Wilkie GM, Jones MM et al (2007) Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110(4):1123\u20131131","journal-title":"Blood"},{"issue":"10","key":"19_CR14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/nrc1452","volume":"4","author":"LS Young","year":"2004","unstructured":"Young LS, Rickinson AB (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4(10):757\u2013768","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"19_CR15","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1128\/JVI.68.11.7374-7385.1994","volume":"68","author":"J Tierney","year":"1994","unstructured":"Tierney J, Steven N, Young LS et al (1994) Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol 68(11):7374\u20137385","journal-title":"J Virol"},{"key":"19_CR16","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood.V91.8.2925.2925_2925_2934","volume":"91","author":"MA Roskrow","year":"1998","unstructured":"Roskrow MA, Suzuki N, Gan Y-J et al (1998) EBV-specific cytotoxic T lymphocytes for the treatment of patients with EBV positive relapsed Hodgkin\u2019s disease. Blood 91:2925\u20132934","journal-title":"Blood"},{"issue":"4","key":"19_CR17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/00002371-200407000-00008","volume":"27","author":"CM Bollard","year":"2004","unstructured":"Bollard CM, Straathof KC, Huls MH et al (2004) The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother 27(4):317\u2013327","journal-title":"J Immunother"},{"issue":"4","key":"19_CR18","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/annonc\/mdr341","volume":"23","author":"WK Chia","year":"2012","unstructured":"Chia WK, Wang WW, Teo M et al (2012) A phase II study evaluating the safety and efficacy of an adenovirus DLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Ann Oncol 23(4):997\u20131005","journal-title":"Ann Oncol"},{"issue":"8","key":"19_CR19","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1182\/blood-2007-05-091280","volume":"110","author":"CM Bollard","year":"2007","unstructured":"Bollard CM, Gottschalk S, Leen AM et al (2007) Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110(8):2838\u20132845","journal-title":"Blood"},{"issue":"8","key":"19_CR20","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","volume":"32","author":"CM Bollard","year":"2014","unstructured":"Bollard CM, Gottschalk S, Torrano V et al (2014) Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol 32(8):798\u2013808","journal-title":"J Clin Oncol"},{"issue":"6","key":"19_CR21","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3109\/14653241003709686","volume":"12","author":"CR Cruz","year":"2010","unstructured":"Cruz CR, Hanley PJ, Liu H et al (2010) Adverse events following infusion of T cells for adoptive immunotherapy: a 10 year experience. Cytotherapy 12(6):743\u2013749","journal-title":"Cytotherapy"},{"issue":"9","key":"19_CR22","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/nrclinonc.2012.111","volume":"9","author":"CM Bollard","year":"2012","unstructured":"Bollard CM, Rooney CM, Heslop HE (2012) T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol 9(9):510\u2013519","journal-title":"Nat Rev Clin Oncol"},{"key":"19_CR23","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1146\/annurev.immunol.25.022106.141553","volume":"25","author":"AD Hislop","year":"2007","unstructured":"Hislop AD, Taylor GS, Sauce D et al (2007) Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 25:587\u2013617","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"19_CR24","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3109\/14653249.2011.561983","volume":"13","author":"CM Bollard","year":"2011","unstructured":"Bollard CM, Gottschalk S, Huls MH et al (2011) Manufacture of GMP-grade cytotoxic T lymphocytes specific for LMP1 and LMP2 for patients with EBV-associated lymphoma. Cytotherapy 13(5):518\u2013522","journal-title":"Cytotherapy"},{"issue":"4","key":"19_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/CJI.0000000000000014","volume":"37","author":"MC Ngo","year":"2014","unstructured":"Ngo MC, Ando J, Leen AM et al (2014) Complementation of antigen presenting cells to generate T lymphocytes with broad target specificity. J Immunother 37(4):193\u2013203","journal-title":"J Immunother"},{"issue":"2","key":"19_CR26","first-page":"S148","volume":"21","author":"SK Perna","year":"2015","unstructured":"Perna SK, Gottschalk S, Torrano V et al (2015) Administration of LMP-specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive lymphoma post allogeneic stem cell transplant. BBMT 21(2):S148","journal-title":"BBMT"},{"issue":"6","key":"19_CR27","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/j.jcyt.2015.03.362","volume":"17","author":"R Miller","year":"2015","unstructured":"Miller R, Perna SJ, Gottschalk S et al (2015) Administration of LMP-specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive lymphoma post allogeneic stem cell transplant. Cytotherapy 17(6):S18","journal-title":"Cytotherapy"},{"key":"19_CR28","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1073\/pnas.70.1.190","volume":"70","author":"G Miller","year":"1973","unstructured":"Miller G, Lipman M (1973) Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci U S A 70:190\u2013194","journal-title":"Proc Natl Acad Sci U S A"},{"key":"19_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1089\/scd.1.1995.4.73","volume":"4","author":"CA Smith","year":"1995","unstructured":"Smith CA, Ng CYC, Heslop HE et al (1995) Production of genetically modified EBV-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother 4:73\u201379","journal-title":"J Hematother"}],"container-title":["Methods in Molecular Biology","Epstein Barr Virus"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-6655-4_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T12:16:52Z","timestamp":1601209012000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-6655-4_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,22]]},"ISBN":["9781493966530","9781493966554"],"references-count":29,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-6655-4_19","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,22]]},"assertion":[{"value":"22 November 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}